OCUL OCULAR THERAPEUTIX, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1393434 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.7%
TTM net income YoY-30.9%
TTM EPS YoY-0.7%
Revenue 3-yr CAGR-4.4%
Net income 3-yr CAGR—
Margins
Gross margin87.3%
Operating margin-680.9%
Net margin-648.6%
FCF margin-530.0%
EBITDA margin-667.4%
Returns
ROE-93.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.10x
Leverage & solvency
Liabilities / assets27.2%
Debt / equity0.00x
Current ratio9.12x
Interest coverage-30.59x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue27.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $51.95M | $63.72M | $58.44M | $51.49M | $43.52M |
| Cost of revenue | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M |
| Gross profit | $45.38M | $58.10M | $53.16M | $46.95M | $39.12M |
| R&D expense | $197.10M | $127.64M | $61.05M | $53.46M | $50.08M |
| SG&A expense | $64.38M | $60.65M | $33.94M | $32.22M | $31.88M |
| Operating income | -$270.02M | -$171.78M | -$82.38M | -$78.65M | -$78.04M |
| Interest expense | $11.84M | $13.58M | $11.34M | $7.02M | $6.67M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$265.94M | -$193.51M | -$80.74M | -$71.04M | -$6.55M |
| EBITDA | -$265.69M | -$168.00M | -$79.40M | -$76.55M | -$75.62M |
| EPS (basic) | -1.42 | -1.22 | -1.01 | -0.92 | -0.09 |
| EPS (diluted) | -1.42 | -1.22 | -1.02 | -0.97 | -0.98 |
| Weighted avg. shares (diluted) | 187.24M | 158.27M | 85.60M | 82.64M | 82.16M |
| Balance sheet | |||||
| Cash & equivalents | $737.06M | $393.72M | $195.81M | $104.06M | $165.93M |
| Receivables | $30.65M | $32.39M | $26.18M | $21.32M | $21.14M |
| Inventory | $3.56M | $3.04M | $2.31M | $1.97M | $1.25M |
| Current assets | $782.13M | $440.99M | $232.24M | $129.63M | $191.30M |
| PP&E, net | $19.68M | $9.39M | $11.74M | $9.86M | $6.96M |
| Total assets | $808.06M | $457.94M | $252.06M | $149.29M | $204.89M |
| Current liabilities | $50.81M | $41.35M | $34.90M | $31.39M | $26.34M |
| Total liabilities | $153.75M | $142.59M | $160.93M | $113.91M | $116.89M |
| Shareholders' equity | $654.31M | $315.34M | $91.13M | $35.38M | $88.00M |
| Shares outstanding | 215.93M | 157.75M | 114.96M | 77.20M | 76.73M |
| Cash flow statement | |||||
| Operating cash flow | -$204.88M | -$134.68M | -$70.23M | -$59.60M | -$65.55M |
| Capital expenditure | $12.01M | $1.29M | $6.09M | $3.71M | $1.19M |
| Free cash flow | -$216.89M | -$135.97M | -$76.32M | -$63.32M | -$66.74M |
| Investing cash flow | -$11.88M | -$1.29M | -$6.09M | -$3.71M | -$1.19M |
| Financing cash flow | $561.72M | $332.11M | $169.83M | $1.45M | $2.85M |
| Depreciation & amortization | $4.32M | $3.79M | $2.98M | $2.11M | $2.42M |
| Stock-based compensation | $43.18M | $33.11M | $17.82M | $16.96M | $14.98M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.